Efficacy analysis of subcutaneous injection of granulocyte-macrophage colony-stimulating factor for prevention of invasive fungal disease in patients with multiple myeloma
10.3760/cma.j.cn115356-20220723-00215
- VernacularTitle:皮下注射粒细胞-巨噬细胞集落刺激因子预防多发性骨髓瘤患者侵袭性真菌病效果分析
- Author:
Yaoyao TIAN
1
;
Xiushuai DONG
;
Yuyue REN
;
Xiaoyun LI
;
Haibin DAI
;
Jinghua WANG
;
Weiwei ZHAO
;
Yuying CHANG
;
Xi CHEN
;
Wei WANG
Author Information
1. 哈尔滨医科大学附属第二医院血液科，哈尔滨 150081
- Keywords:
Multiple myeloma;
Granulocyte-macrophage colony-stimulating factor;
Invasive fungal disease;
Invasive fungal infections
- From:
Journal of Leukemia & Lymphoma
2023;32(5):284-288
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy of subcutaneous injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in preventing invasive fungal disease (IFD) in patients with multiple myeloma (MM).Methods:The clinical data of 222 patients who were admitted to the Second Hospital of Harbin Medical University from January 2015 to June 2021 were retrospectively analyzed. The patients was given GM-CSF (3-5 μg·kg -1·d -1, GM-CSF group) or granulocyte colony-stimulating factor (G-CSF, 2-5 μg·kg -1·d -1, G-CSF group) when neutrophils (ANC) ≤1.5×10 9/L after induction chemotherapy. Patients were discontinued when white blood cell count (WBC) ≥10.0×10 9/L. The incidence of IFD (including confirmed, clinical and proposed diagnosis) and breakthrough invasive fungal infections was compared between the two groups. Results:The incidence of IFD was 8.1% (18/222) in all patients. The incidence of IFD was 3.5% (3/85) and 10.9% (15/137) in the GM-CSF and G-CSF groups, respectively, and the difference between the two groups was statistically significant ( χ2 = 3.88, P = 0.049). In 9 patients of GM-CSF group receiving fungal infection prophylaxis and in 15 patients of G-CSF group receiving fungal infection prophylaxis, the incidence of breakthrough invasive fungal infections was 0 and 7 cases, respectively, and the difference between the two groups was statistically significant ( P = 0.022). Conclusions:GM-CSF application in MM patients can reduce the incidence of IFD and breakthrough invasive fungal infections.
